|Small cell lung cancer is an aggressive disease that is usually disseminated at the
time of initial diagnosis. The natural history is characterized by a rapid and relentless
clinical course with a median survival measured in weeks to months, depending on the
extent of the disease. SCLC exhibits considerable sensitivity to a number of cytotoxic
agents and systemic combination chemotherapy is the cornerstone of treatment. Most
regimens used today include
Etoposide and a platinum analog, either Cisplatin or Carboplatin. In patients with
limited-stage disease, thoracic irradiation is also delivered; this provides improved
local control and meta-analysis has shown that it also contributes to a survival benefit.
Overall response rates are in the range of 70% - 90% with complete responses as high as
50% in those patients with limited disease and up to 30% in those with extensive SCLC.
More complex treatment regimens employing additional cytotoxic drugs, dose
intensification, alternating regimens (as in the above patient), and complicated weekly
intensive regimens have yet to consistently demonstrate
significant improvement in survival over standard therapy. Median survival for extensive
SCLC is approximately 8-10 months and for a limited SCLC approximately 12-16 months.
Recent pilot studies using concurrent chemotherapy with twice daily irradiation have shown
improved overall (9%) and complete (approximately 8-9%)
response rates and median survival approximately two years.
The advantage twice daily fractionation over single daily irradiation was not confirmed in
a recent prospective randomized trial. SCLC has a propensity to metastasize to the central
nervous system. Patients who obtain complete response to chemotherapy, and thus live
longer, are at particular risk to develop brain metastases. This complication can be
reduced significantly with prophylactic cranial irradiation (PCI). Although there have
been concerns that some patients may develop radiation-related neuropsychological
disturbances, recent prospective, randomized data suggest that PCI can reduce the risk of
brain metastases without a significant increase in treatment-related complications.
SCLC is almost invariably associated with a history of smoking and these patients are also
at considerable risk for other tobacco-related malignancies. Although late relapses from
SCLC can occur, recurrence after a 5-year disease-free interval are distinctly unusual.
Indeed, in long-term survivors of SCLC there is an increasing risk of second aerodigestive
cancers and there is a greater likelihood of succumbing to a second primary tumor than
from recurrent SCLC. Those patients who appear to have been cured of SCLC would be good
candidates to target for chemoprevention trials.
Breast Cancer Treatment
News release of 2 year study trails
Penetration of cell tumor was achieved with an addition of a solvent, that had no action
on the tumor cell itself, but was used as a vehicle, penetrating the tissues to carry
AMYLOXINE® to the
protoplasm thereby inactivating and therefore starved the cancer cells to death. Because
AMYLOXINE® alkaline nature, it is tumor specific to the nucleic acid of tumor cells.
have the ability to absorb and transpose AMYLOXINE® from their nucleus, cancer cells can
transpose AMYLOXINE®. AMYLOXINE® was used in 212 breast cancer patients
over a two year
period. With a 92% remission rate, by injection only,
thereby eliminating surgery.